Last updated on August 2019

Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ductal Carcinoma In Situ | Progesterone Receptor Negative | Estrogen Receptor Negative | Breast Cancer
  • Age: - 100 Years
  • Gender: Female

Inclusion Criteria:

  • Must be concurrently enrolling to Alliance A011502. Eligible patients may be either pre- or post-menopausal.
  • Patients must have hormone receptor-negative breast cancer.
  • Patients must have baseline breast density measurement as defined by one of the
    following
  • >= 25% breast density, or
  • Scattered areas of fibroglandular density, or
  • Breast composition category b, c, or d, per Breast Imaging Reporting and Data System (BI-RADS) 2013.
  • Baseline digital screening mammogram (mediolateral [MLO] and craniocaudal [CC] views) taken within 8 weeks prior to registration must be available for submission.
    • If baseline mammogram within 8 weeks is not available, a new screening mammogram must be performed prior to treatment on Alliance A011502. To receive reimbursement for the cost of this additional mammogram, institutions may submit the A211601 Reimbursement Form, which is available on the Alliance and Cancer Trials Support Unit (CTSU) web pages.
  • Patients receiving endocrine therapy (e.g., tamoxifen, aromatase inhibitors) are not eligible.
  • Contralateral unaffected breast in place (with no prior cancer or radiation, no implants and no plan for breast surgery on contralateral breast over the course of the study). Patients with a prior biopsy on the unaffected breast are eligible.
  • Not pregnant and not nursing.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.